GUIDE

2026 Playbook for Specialty Medication Onboarding & Adherence

 

Specialty medications are reaching a tipping point. With 50+ novel drugs launching annually and 98 million prescriptions abandoned in 2024, traditional approaches to patient onboarding are breaking down. Prior authorization delays, fragmented workflows, and disconnected patient support programs create friction at every stage.

 

Get the Full Playbook

PLAYBOOK PREVIEW
Read Chapter 1
Capacity Constraints: Time and Resource Scarcity at Crucial Intervention Points

Getting patients on therapy still depends on people—clinicians, staff, patient support program managers, and hub services teams—working in systems that weren’t built for today’s complexity. These legacy systems typically don’t communicate well with each other, creating friction at every stage of the medication journey from prescribing to ongoing adherence.

Doctor visits typically last 15-20 minutes, sometimes less. During these brief encounters, providers must address patients’ concerns, review medical history, assess multiple chronic conditions, and manage documentation in the electronic health record (EHR) system. When specialty medications are added to the mix, there’s barely time to cover side effects, dosing instructions, or financial assistance options. In fact, the average provider spends 36 minutes on EHR tasks per patient visit, longer than the face-to-face time.3

Managing prior authorization (PA) is a major contributor to clinician workflow inefficiencies. This is particularly true for specialty medications. When prescribers lack real-time visibility into PA requirements, alternative formulary options, or affordability based on patient-specific coverage details, they may write prescriptions that trigger avoidable delays. By the time barriers surface, often days later, the critical window for first-fill success has already narrowed.

Beyond the clinic, patient support hub services are scaling up to meet demand, but the expansion itself signals strain. The hub services market now includes more than 90 vendors, with several doubling staff year-over-year to meet demand.4

This rapid scaling suggests more than simple market growth. It reflects an operational model struggling to maintain personalized support as specialty medication launches accelerate, and patient populations expand.

When capacity lags demand, response times lengthen, and patient motivation erodes.

What’s Reshaping Specialty Medication Success?

Specialty drugs are transforming the economics of medication access. Between 2024 and 2028, 50-55 novel drugs are expected to launch annually, with specialty and orphan drugs dominating approvals.1 With 75% of drugs in development now classified as specialty, every new launch adds more strain.2

PLAYBOOK PREVIEW
Read Chapter 2
Economic Squeeze: Rising Costs Meet Coverage Constraints

In 2024, 98 million new prescriptions were abandoned at U.S. pharmacies.5 Each one represents a moment when the promise of treatment collided with the reality of access barriers.

For specialty medications, 100% of which require PA, according to America’s Health Insurance Plans (AHIP) analysis, patients may even assume that the prescribed therapy isn’t needed if the PA does not receive immediate approval.6

The Inflation Reduction Act’s $2,000 annual out-of-pocket cap for Medicare Part D, which took effect in January 2025, addresses cost exposure for 3.2 million Medicare beneficiaries.7 Yet 30% of adults across all payer types still report difficulty affording their medications.8 For commercially insured patients and those in high-deductible plans, PA denials and first-fill affordability barriers can stop therapy in its tracks.

When patients abandon their prescriptions, pharmaceutical companies lose the opportunity to improve health outcomes, capture real-world evidence (RWE) of their therapies’ effectiveness, and build market share. 

This is only a preview! Want to read more?

Get remaining chapters on the ROI of upstream intervention, real-world evidence strategies, and proven Timely results with 450,000+ prescribers.

Timely-Playbook-Email-Header-B

Sources

1. Understanding the Use of Medicines in the U.S. 2025. IQVIA.
2. Szczotka, Andy, Pharm.D. Navigating the rapid growth of specialty drugs: opportunities, challenges, and the path ahead. Pharmacy Times – Pharmacy Practice News and Expert Insights. Published March 24, 2025.
3. Rotenstein LS, Holmgren AJ, Horn DM, et al. System-Level Factors and Time Spent on Electronic Health Records by Primary Care Physicians. JAMA Netw Open. 2023;6(11):e2344713. doi:10.1001/jamanetworkopen.2023.44713
4. Access Market Intelligence. Specialty Hub Services/Patient Assistance Providers 2025 Overview - Access Market Intelligence. Access Market Intelligence. Published May 31, 2025.
5. The Use of Medicines in the U.S. 2024: Usage and spending Trends and Outlook to 2028. IQVIA.
6. Emerson J. Most common treatments subject to prior authorization. Becker’s Payer Issues | Payer News. Published November 23, 2022.
7. Cubanski J, Neuman T, Damico A. Millions of People with Medicare Will Benefit from the New Out-of-Pocket Drug Spending Cap Over Time. KFF. Published September 8, 2025.
8. Sparks G, Kirzinger A, Montero A, Valdes I, Hamel L. Public opinion on prescription drugs and their prices. KFF. Published August 9, 2025.